Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Ly
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
| Condition(s) | Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL, HGBCL, FL Lymphoma, Lymphoplasmacytic Lymphoma, Follicular Lymphoma (FL) |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma |
| Who can participate | Inclusion Criteria: * Participant must be ≥ 18 years of age. * Participant has a confirmed diagnosis of large B-cell lymphoma (including DLBCL, high-grade B-cell lymphoma \[HGBCL\], primary mediastinal B-cell lymphoma \[PMBCL\], etc), FL, MCL, marginal zone lymphoma, transformation of indolent B-cell lymphoma, or lymphoplasmacytic lymphoma, including Waldenstrom macroglobulinemia. * Participant has relapsed or progressed on at least 2 prior lines of therapy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * All participants must have measurable disease via computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT. * Documented CD19 or CD20 positivity of their B-cell neoplasm based on any representative pathology report fr |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | ModeX Therapeutics, An OPKO Health Company |
| Locations | Richmond, Victoria, Australia; Nedlands, Western Australia, Australia |
| Start date | 2026-04-13 |
| NCT ID | NCT07249905 |
| Official listing | https://clinicaltrials.gov/study/NCT07249905 |